---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125307"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:43:04.660894+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q3 rev $3.1M, cash $330.5M; FT819/FT522/FT825 clinical progress

## Summary
- Q3 revenue of $3.1M from Ono collaboration; total op expense $55.5M incl $11.8M stock comp.
- Cash, equivalents & investments $330.5M; projected operating runway through end of 2026.
- FT819 Phase 1 SLE: 3 patients dosed with fludarabine-free conditioning; no DLTs/CRS/ICANS/GvHD; data at ACR and ASH.
- FT522 IND allowed for B cell-mediated autoimmune basket study; initial BCL clinical data at ACR Convergence.
- FT825/ONO-8250 initial solid tumor data: safety profile favorable, CAR T expansion with activated phenotype at 100M dose.

## SEC filing metadata
- accession: 0000950170-24-125307
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/0000950170-24-125307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017024125307/fate-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125307
- JSON: https://secwatch.observer/filing/0000950170-24-125307.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.